Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin

Cell Biology and Toxicology

Volumn 13, Issue 4-5, 1997, Pages 365-374

  Li, A P ^a   Jurima Romet, M ^b  

^a In Vitro Technologies Inc   (United States)

^b Bureau of Drug Research   (Canada)

Author keywords

Drug development; Drug interactions; Drug metabolism; Drug toxicity; Human hepatocytes; Pharmacokinetics; Rifampin; Terfenadine

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; ISOENZYME; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; NARINGENIN; RIFAMPICIN; TERFENADINE; TESTOSTERONE; TROLEANDOMYCIN;

AGE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CULTURE; LIVER METABOLISM; PRIORITY JOURNAL; TECHNIQUE;

CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; LIDOCAINE; LIVER; MIXED FUNCTION OXYGENASES; RIFAMPIN; STEROID HYDROXYLASES; TERFENADINE;

EID: 0030803654     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007451911843     Document Type: Conference Paper

References (38)

1. Badcock NR, Bartholomeusz FD, Frewin DB, Sansom LN, Reid JG. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol. 1987;33:531-4.
2. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA. Clin Pharmacol Ther. 1989;46:521-7.
3. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol. 1996;59:383-8.
4. Burke MD, Mayer RT. Different effects of phenobarbitone and 3-methylcholanthrene induction of the hepatic microsomal metabolism and cytochrome P450 binding of phenoxazone and a homologous series of its n-alkyl ethers. Chem Biol Interact. 1993;45:243-58.
5. Daneshmend T, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988;14:13-34.
6. D'Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm. 1986;20:353-62.
7. Dellerich M, Raude E, Burdelski M et al. Monoethylglycine-xylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem. 1987;25:845-53.
8. Donato MT, Castell NV, Gomez-Lechon MJ. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos. 1995;23:256-8.
9. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet. 1993;24:472-95.
10. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953-1040.
11. FDA. Warnings issued on nonsedating antihistamines terfenadine and astemizole. J Am Med Assoc. 1992;268:705.
12. Gartiez DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim Forsch Drug Res. 1982;32:1185-90.
13. Ged C, Roullion JM, Pichard L et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker for human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol. 1989;38:373-87.
14. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev. 1989;40:243-88.
15. Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Safety. 1994;11:242-51.
16. Grant SM, Clissold SP. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310-44.
17. Guengerich FP. Metabolism of 17α-ethynylestradiol in humans. Life Sci. 1990;47:1981-8.
18. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetics and electrocardiographic consequences. J Am Med Assoc. 1993a;269:1513-8.
19. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol. 1993b;33:1201-6.
20. Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol. 1996;36:345-51.
21. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-83.
22. Imaoka S, Enomoto K, Yutaka O et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther. 1990;255:1385-91.
23. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos. 1994;22:849-57.
24. Jurima-Romet M, Huang HS, Beck DJ, Li AP. Evaluation of drug interactions in intact hepatocytes: inhibitors of terfenadine metabolism. Toxicol In Vitro. 1996;10:655-63.
25. Li AP. Primary human hepatocytes as an experimental system in toxicology and drug metabolism. Comments Toxicol. [in press].
26. Li AP, Roque MA, Beck DJ, Kaminski DL. Isolation and culturing of hepatocytes from human liver. J Tissue Culture Methods. 1992;14:139-46.
27. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P4503A4. Toxicology. 1995a;104:1-8.
28. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther. 1995b;274:673-7.
29. Loretz LJ, Li AP, Flye MW, Wilson AGE. Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica. 1989;19:489-98.
30. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc. 1990;264:2788-90.
31. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics: effects of age and various pathophysiological states. Clin Pharmacokinet. 1989;16:193-214.
32. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992;41:1047-55.
33. Pohjala-Sintonen S, Viitsalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. Br Med J. 1993;306:186.
34. Reimers D, Nocke-Finck L, Breuer H. Rifampicin and the "pill" do not go well together. J Am Med Assoc. 1974;227:608.
35. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P450. Arch Biochem Biophys. 1987;255:27-41.
36. Strolin Benedetti M, Dostert P. Induction and autoinduction of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect. 1994;102:101-5.
37. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc. 1993; 269:1532-6.
38. Yun CH, Okerholm A, Guengerich FP. Oxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P4503A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos. 1993;21:403-9.